Compare Stocks

Americas Technology Acquisition Corp. does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, recapitalization, reorganization, or similar business combination in the technology, media, and telecommunications sector. The company was incorporated in 2020 and is based in Dallas, Texas.

Delwinds Insurance Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the insurance and insurtech sectors. The company was incorporated in 2020 and is based in Houston, Texas.

EpicQuest Education Group International Limited, through its subsidiaries, provides education solutions for students interested in college and university programs in the United States and internationally. The company offers English proficiency educational programming and transfer pathways for students pursuing academic degrees; and operates a career-training college. It also operates and manages the U.S. coordination projects and services during and after studying abroad, including student dormitory management, academic guidance, international student services, student catering services, student transfer application services, internship and employment guidance, lawyer services, medical services, and student entrepreneurship services. In addition, the company acts as a recruiting agent for the University of the West of Scotland and Coventry University; offers educational programs related to kinesiology and recreation education; and organizes sports-related entertainment projects. The company was formerly known as Elite Education Group International Limited and changed its name to EpicQuest Education Group International Limited in August 2022. The company was founded in 2012 and is headquartered in Middletown, Ohio.

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Presidio is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. Our office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California. While geographical clustering of real estate enables us to reduce our operating costs through economies of scale by servicing several properties with less staff, it makes us susceptible to changing market conditions in these discrete geographic areas, including those that have developed as a result of COVID-19. Presidio owns approximately 6.5% of the outstanding common stock of Conduit Pharmaceuticals Inc., a disease agnostic multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development.